pyrroles has been researched along with Island Cell Tumor in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, S; Fujishima, F; Imai, H; Ishioka, C; Kobayashi, A; Komine, K; Saijo, K; Sato, N; Shimodaira, H; Shirota, H; Shuin, T; Sugiyama, S; Takahashi, M; Takahashi, S | 1 |
| Hanahan, D; Pietras, K | 1 |
| Schein, PS | 1 |
1 review(s) available for pyrroles and Island Cell Tumor
| Article | Year |
|---|---|
Chemotherapeutic management of the hormone-secreting endocrine malignancies.
Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Aminoglutethimide; Aniline Compounds; Antibiotics, Antineoplastic; Antineoplastic Agents; Butanones; Carcinoid Tumor; Diazoxide; Humans; Hypoglycemia; Insulin Antagonists; Kidney Tubules; Metyrapone; Mitotane; Neoplasm Metastasis; Pheochromocytoma; Pyrimidines; Pyrroles; Pyrrolidines; Ribonucleosides; Serotonin Antagonists; Streptozocin | 1972 |
2 other study(ies) available for pyrroles and Island Cell Tumor
| Article | Year |
|---|---|
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
Topics: Adenoma, Islet Cell; Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2016 |
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Topics: Adenoma, Islet Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Clinical Protocols; Cyclophosphamide; Disease Models, Animal; Endothelial Cells; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sunitinib | 2005 |